Today on DrugResearcher.com   Alzheimer's hits glaucoma between the eyes ChanTest to expand ion-channel screening Covance, Nanostream, launch new discovery services Pfizer's GORD therapy enters the clinic Entelos to develop liver injury model for the FDA

Related Industry News   Court sanctions independent trustee for Inyx USA Lab equipment manufacturers see record growth Celsis tech gets pharma recognition GSK increases H5N1 vaccine presence in US

Breaking News on Drug Discovery
Daily  Tuesday 07 August 2007		Forward to a colleague

	Sponsored Message Adenoviral shRNA and cDNA collections As the business service unit for Galapagos, a leading genomics-based drug discovery company, BioFocus DPI offers superior adenoviral tools and services to meet your target discovery and validation needs... Click Here Access Full Stories Alzheimer's hits glaucoma between the eyes UK researchers have published results linking the beta amyloid protein associated with Alzheimer's disease to glaucoma, opening up a much needed new target for glaucoma therapies... Read ChanTest to expand ion-channel screening ChanTest has received private equity financing by Ampersand Ventures to enable the company to expand its library of ion channel-expressing cell lines for drug screening... Read Covance, Nanostream, launch new discovery services Contract research organisation (CRO) Covance and laboratory services firm Nanostream have both recently launched new drug discovery offerings... Read Pfizer's GORD therapy enters the clinic Pfizer has initiated a Phase I study for its gastro oesophageal reflux disease (GORD or GERD using the US spelling) therapy that it licensed from Kosan Biosciences, in a deal worth up to $250m (€181m)... Read Entelos to develop liver injury model for the FDA The search for better models to predict drug-induced human liver damage has led the FDA (US Food and Drug Administration) to turn to Entelos to design a 'virtual liver' to guide biomarker and assay development... Read
	All News Headlines for: August | July | June
	Product Overview Pre-Clinical Contract Research - Free Download Pharmatest offers unique preclinical in vitro and in vivo drug efficacy testing services to pharmaceutical companies developing new drugs against osteoporosis, cancer or osteoarthritis. Our services can also be used for testing existing compounds for possible adverse effects on bone or secondary indication for bone-related diseases, as well as development of functional foods for bone health... Click Here
	Related Industry News Court sanctions independent trustee for Inyx USA A US bankruptcy court judge ruled on Friday that Puerto Rican-based pharma services firm Inyx USA be put under the control of an independently-appointed trustee... Read Lab equipment manufacturers see record growth With second quarter financial results being released thick and fast, laboratory instrument manufacturers Bruker Biosciences and Illumina have both seen very strong revenue growth... Read Celsis tech gets pharma recognition Celsis' Rapid Microbiological Method has been included in GlaxoSmithKline's (GSK) successful Veramyst New Drug Application, paving the way for broader acceptance of the time saving technique... Read GSK increases H5N1 vaccine presence in US GlaxoSmithKline (GSK) is bolstering its pandemic H5N1 vaccine presence in the US after being awarded a contract to provide 22.5 million doses of bulk antigen to the US stockpile while launching clinical trials... Read Outsourcing-Pharma.com special focus Latest twists and turns in Inyx saga The latest twists and turns in the Inyx Inc. bankruptcy saga include an attempted power seize by its creditor, fraud allegations thrown around courtrooms and in the media, the resignation of Inyx' accountants, and increasing signs of links between Inyx and a company called Karver. Read Sponsored Message Live cell-based assay with Bionas® 2500 analyzing system Bionas® 2500 measures multiple metabolic parameters simultaneously like acidification, oxygen consumption and adhesion of living cells. Metabolic and cytotoxic effects can be visualized as changes of these parameters in dependence of test compounds... Click Here Previous Headlines Asuragen moves ahead with microRNA offering Asuragen has launched a newly expanded miRNA expression profiling service that can search over 13,000 human candidate miRNAs... Read PharmaNet back in the red; lawsuit settled PharmaNet has reported second quarter results that place it back in the red after it had only just clawed its way back into the black in the first quarter, following a string of quarterly losses... Read HIV therapy leads way in personalised medicine GlaxoSmithKline (GSK) has opened the flood gates into the world of personalised medicine with the world's first ever approved genetic test, which predicts a life threatening side effect of one of its antiretroviral... Read MDS Pharma expands services in EU market MDS Pharma Services has announced it is expanding its development and regulatory services (DRS) business in Europe while its bioanalytical operations are still struggling.  ... Read PADI dives into the chemical analysis of solids UK researchers have developed a new way to make compounds fly into a mass spectrometer (MS) that could provide benefits for researchers working in drug discovery and quality control (QC) laboratories... Read Product Innovation Alerts - Free of Charge Indicate your research interests and receive alerts on relevant products and market innovations Analysis and instrumentation Assays and screening Cell culture & Equipment Chromatography Compounds and consumables Contract services (outsourcing) Drug discovery Genomics / Proteomics Informatics & IT Lab equipment & consumables Liquid handling and automation Liquid handling and sample preparation Production technologies Separation and purification

Free Newsletters for Pharmaceuticals Access now !Choose from over 20 industry e-newsletters Access Decision News Media e-newsletters for the food, beverage & nutrition industries, click here

Forward to a colleague

	To continue to receive this newsletter in your inbox, please add newsletter@DrugResearcher.com to your address book
	Update preferences | Change your email address | Unsubscribe
	Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback
	© 2007 - Decision News Media S.A.S - All Rights Reserved La Tour du Triangle - 26, allee Jules Milhau - 34000 Montpellier - France http://www.decisionnewsmedia.com